NUVB-WT — Nuvation Bio Inc.

Summary of Nuvation Bio's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $41.9 million, contributing to a total of $62.9 million for the full year.
• IBTROZI Product Revenue: $15.7 million in Q4 and $24.7 million for the full year.
• Cash Position: $529.2 million at year-end, bolstered by a $60 million upfront payment from Eisai.
• Gross to Net Ratio: Approximately 25%, expected to increase slightly as more contracts are established.

2. Strategic Updates and Business Highlights

• IBTROZI Launch: Full FDA approval received on June 11, 2025, with 432 new patients starting treatment by year-end, including 216 in Q4.
• Market Penetration: IBTROZI is being prescribed at a rate 6x faster than previous ROS1 TKI launches, with a strong focus on expanding the prescriber base and treating newly diagnosed patients.
• Partnerships: Strategic collaboration with Eisai for European and other international markets, with potential milestone payments totaling nearly $520 million.
• Pipeline Development: Progress on safusidenib for IDH1 mutant glioma, with ongoing Phase III trials and a new non-pivotal cohort for grade 3 oligodendroglioma.

3. Forward Guidance and Outlook

• 2026 Revenue Expectations: While no specific guidance was provided, management expressed confidence in meeting consensus estimates of $150 million, driven by increasing first-line patient starts.
• Patient Start Trends: Continued focus on capturing first-line patients, with expectations that revenue growth will align with new patient starts over time as more patients transition from later lines of therapy.

4. Bad News, Challenges, or Points of Concern

• Revenue Growth Lag: Discrepancy between new patient starts and revenue growth due to a significant portion of patients starting IBTROZI in later lines, which typically have shorter durations of response.
• Market Competition: Potential competitive pressures from other therapies entering the second-line setting later in 2026.
• Discontinuation Rates: High discontinuation rates observed in later-line patients (75% of discontinuations), which could impact revenue stability.

5. Notable Q&A Insights

• Patient Mix: Majority of new patient starts currently in later lines, with management optimistic about increasing first-line use as the launch matures.
• Regulatory Engagement: Ongoing efforts to secure a favorable position for IBTROZI in NCCN guidelines to enhance first-line adoption.
• Safusidenib Enrollment: Confidence in enrollment for the Phase III trial, with no plans for interim analysis before the projected 2029 completion.
• Market Dynamics: Management emphasized the importance of educating physicians on the benefits of IBTROZI, particularly regarding CNS penetration compared to crizotinib.

Overall, Nuvation Bio demonstrated a strong launch trajectory for IBTROZI, with significant revenue potential moving forward, albeit tempered by challenges related to patient mix and competition in the oncology landscape.